CONSORT flow diagram.

Akihiro Hirakawa (309166); Atsushi Tashiro (4849840); Azusa Mano (4849861); Chikako Ogawa (2450101); Chiyo Suzuki (4849864); Hideki Muramatsu (840463); Hiroyuki Kidokoro (4014998); Jun Natsume (4849858); Jun-ichi Kawada (3901243); Masahiko Ando (579876); Masahiro Hayakawa (4849867); Midori Suzumura (4849837); Satoshi Hayano (4849846); Sayako Hamazaki (4849843); Seiji Kojima (352230); Shin Hoshino (4849852); Takafumi Niwa (4849834); Takeshi Tsuji (1673656); Yoshiaki Sato (2170141); Yoshihiro Tanahashi (4849855); Yuichiro Sugiyama (4849849)

Abstract

<p>Progression of patients through the trial up to 3 weeks of treatment in all participating centers. No patients dropped out due to adverse events in either group.</p

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/58843...

Last time updated on 14/03/2018